Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy

Preiswerk, Benjamin; Rudiger, Alain; Fehr, Jan; Corti, Natascia

doi:10.1007/s15010-012-0300-3

Cited by 16 publications

(10 citation statements)

References 24 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preiswerk et al . showed that daptomycin exposure in critically ill patients undergoing CRRT after once‐daily dosing was similar to that in ICU patients with normal renal function. In the study by Rudiger et al .…”

Section: Discussionmentioning

confidence: 86%

“…Overall, our results are largely consistent with those from Preiswerk et al . and Rudiger et al . , who also concluded that daily‐dosing regimens with daptomycin are more appropriate than dosing every second day in CRRT patients.…”

Section: Discussionmentioning

confidence: 92%

“…Other authors have also shown that Q24 h dosing is a more appropriate dosing strategy in patients undergoing CRRT without the risk of exposure above the target ranges . Preiswerk et al .…”

Section: Discussionmentioning

confidence: 99%

“…Other authors have also shown that Q24 h dosing is a more appropriate dosing strategy in patients undergoing CRRT without the risk of exposure above the target ranges [32,33]. Preiswerk et al [32] showed that daptomycin exposure in critically ill patients undergoing CRRT after once-daily dosing was similar to that in ICU patients with normal renal function.…”

Section: Figurementioning

confidence: 98%

See 3 more Smart Citations

Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy

Khadzhynov

Peters

et al. 2016

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimThe objective of this population pharmacokinetic (PK) analysis was to provide guidance for the dosing interval of daptomycin in patients undergoing continuous renal replacement therapy (CRRT).MethodsA previously published population PK model for daptomycin was updated with data from patients undergoing continuous veno‐venous haemodialysis (CVVHD; n = 9) and continuous veno‐venous haemodiafiltration (CVVHDF; n = 8). Model‐based simulations were performed to compare the 24 h AUC, C max and C min of daptomycin following various dosing regimens (4, 6, 8, 10, and 12 mg kg−1 every [Q] 24 h and Q48 h), with the safety and efficacy exposure references for Staphylococcus aureus bacteraemia/right‐sided infective endocarditis.ResultsThe previously developed daptomycin structural population PK model could reasonably describe data from the patients on CRRT. The clearance in patients undergoing CVVHDF and CVVHD was estimated at 0.53 and 0.94 l h−1, respectively, as compared with 0.75 l h−1 in patients with creatinine clearance (CrCl) ≥ 30 ml min−1. Daptomycin Q24 h dosing in patients undergoing CRRT resulted in optimal exposure for efficacy, with AUC comparable to that in patients with CrCl ≥ 30 ml min−1. In contrast, Q48 h dosing was associated with considerably lower AUC24–48h in all patients for doses up to 12 mg kg−1 and is therefore inappropriate.ConclusionsQ24 h dosing of daptomycin up to 12 mg kg−1 provides comparable drug exposure in patients on CVVHD and in those with CrCl ≥ 30 ml min−1. Daily daptomycin use up to 8 mg kg−1 doses are appropriate for patients on CVVHDF, but higher doses may increase the risk of toxicity.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 92%

“…Other authors have also shown that Q24 h dosing is a more appropriate dosing strategy in patients undergoing CRRT without the risk of exposure above the target ranges . Preiswerk et al .…”

Section: Discussionmentioning

confidence: 99%

Section: Figurementioning

confidence: 98%

See 2 more Smart Citations

Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy

Khadzhynov

Peters

et al. 2016

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Based on a CRRT model with bovine plasma showing comparable clearance when compared with normal renal clearance [7], we settled for a once daily regimen at our intensive care units at the time. We recently published a retrospective chart analysis of 7 critically ill patients with routinely measured trough and in some cases additional peak concentrations [8]. All of the patients - although undergoing CRRT and receiving daptomycin doses above 6 mg/kg/day once daily in some cases - had daptomycin concentrations below those found in healthy volunteers at the equivalent dose [9,10].…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of Daily Daptomycin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy

Corti¹,

Rudiger²,

Chiesa³

et al. 2013

Chemotherapy

View full text Add to dashboard Cite

Background: The optimal daptomycin dosing regimen for critically ill patients undergoing continuous renal replacement therapy (CRRT) has still to be established. Methods: Daptomycin pharmacokinetics was determined in 9 patients after administration of 6 mg/kg/day over 5 days. Results: At steady state, which was reached by day 3, the area under the curve over 24 h (AUC24h) was 667.4 ± 356.6 mg·h/l, and the maximum concentration (Cmax) was 66.9 ±25.3 mg/l. Mean CRRT clearance accounted for 48% (range 32-67%) of total clearance (mean 10.2 ml/min, range 6.1-18 ml/min). Significant correlations were observed between Cmax, minimum concentration (Cmin) and AUC24h (R² = 0.91, p < 0.001, and R² = 0.94, p < 0.001) and between albumin plasma concentration and free daptomycin (R² = 0.7, p = 0.009). Conclusion: No significant accumulation occurred with a daily daptomycin dose of 6 mg/kg in patients undergoing CRRT with an effluent flow rate of >30 ml/kg/h. The quantification of trough concentrations (Cmin) appears to be a good surrogate to estimate AUC24h and to monitor daptomycin treatment in patients undergoing CRRT.

show abstract

Drug Dosing in Continuous Renal Replacement Therapy (CRRT)

Gallagher

Murray

2016

Core Concepts in Dialysis and Continuous Therapies

View full text Add to dashboard Cite

Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy

Abstract: In critically ill patients undergoing CRRT, daptomycin exposure with once-daily dosing was similar to ICU patients with normal renal function, but lower compared to healthy volunteers. Our data suggest that daptomycin once-daily dosing is appropriate in patients undergoing CRRT.

Cited by 16 publications

References 24 publications

Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy

Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy

Pharmacokinetics of Daily Daptomycin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy

Drug Dosing in Continuous Renal Replacement Therapy (CRRT)

Contact Info

Product

Resources

About